Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Acerus Pharmaceuticals Corp ASPCQ

Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in... see more

OTCPK:ASPCQ - Post Discussion

View:
Post by PitchinPennies on Oct 03, 2022 8:42am

Smell-a-thon

Predictably, Ian met the pay-up deadline for his debt to Serentiy, which had already been extended,  and he decided one more time not to pay up. To convince Serenity that he's not just stringing them along [stifled laughter] he offered to pay a 50% premium on the agreed-to amount for the principal owing. I mean, who wouldn't do that? Fair is fair.

Meanwhile, S-l-o-w Eddie is keeping out of site, just putting in the hours at his other job in the Cinnabon at Seaway Mall. Normally he'd be tweeting "Great news!", or "Fantastic!", or "Keep up the good work, people!", but the photo below illustrates that he's hiding in a dumpster behind the Seaway Mall until this crisis blows over, which it will at the end of this month.

If you'd like to help out and save Acerus, and make it possible to continue paying the salary of executives just like S-l-o-w Eddie, please join our asset sale, M&A, or licensing transaction telethon. Pick up the phone and call Michael Hayes right now at 416 575 9089

Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has amended the promissory note (the “Note”) in the amount of US$4.91 million related to the up-front fee owed to former Serenity Pharmaceuticals LLC (“Serenity”) securityholders. The securityholder representative and Acerus agreed that the amount of the note would be increased to US$7.75 million. 

This amendment will allow Acerus more time to complete its previously announced strategic review.

User image
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities